

## Vital BioTech Holdings Limited

## 維奧生物科技控股有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1164)

## ANNOUNCEMENT PRICE SENSITIVE INFORMATION

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules").

The board of directors ("Board") of Vital BioTech Holdings Limited (the "Company", together with its subsidiaries, the "Group") is informed by Mr. Tao Lung ("Mr. Tao"), the controlling shareholder ("Controlling Shareholder"), executive director and chairman of the Company, that on 8 April 2008, he has transferred 75,000,000 shares of the Company ("Shares"), representing approximately 4.84% of the total issued share capital of the Company as at the date of this announcement, to Mr. Song Ming ("Mr. Song"), at a price of HK\$0.327 per Share (the "Transfer"). The price per Share of the Transfer was determined based on the historical price to earnings ratio of approximately 10 times and represents a premium of approximately 52.09% over the closing price of the Share of HK\$0.215 as at the date of this announcement. The Shares of the Transfer are subject to a lock-up period until 31 December 2008. As informed by Mr. Tao, Mr. Song is a person independent of the Company and its connected persons (as defined in the Listing Rules). Mr. Song is an executive director of C&O Pharmaceutical Technology (Holdings) Limited, a company listed on the Singapore Exchange Securities Trading Limited and is principally engaged in research, manufacturing, marketing and distribution of C&O branded pharmaceutical products. Mr. Song expresses his interests in the Company and is optimistic on the growth potential and future prospects of the Group. The directors are of the view that the introduction of a strategic investor to the Company through the Transfer is beneficial to the Company and its shareholders as a whole.

Upon completion of the Transfer, Mr. Tao is interested in 558,418,588 Shares, representing approximately 36% of the total issued share capital of the Company as at the date of this announcement comprising personal interest of 35,891,648 Shares and indirect interest through Perfect Develop Holding Inc. of 522,526,940 Shares as at the date of this announcement. Mr. Tao remains the Controlling Shareholder upon completion of the Transfer.

By order of the Board
Vital BioTech Holdings Limited
Leung Wai Pong
Company Secretary

Hong Kong, 8 April 2008

As at the date of this announcement, the Board of the Company comprises six executive directors: Mr. Tao Lung, Mr. Huang Jianming, Mr. Shen Songqing, Mr. Liu James Jin, Mr. Xu Xiaofan and Ms. Guo Lin, and three independent non-executive directors: Mr. Lui Tin Nang, Mr. Lee Kwong Yiu and Mr. Chong Cha Hwa.